Effect of Lodradi Ashchyotana in Vataja Abhishyanda (Simple Allergic Conjunctivitis)

A Randomized Controlled Study on the Efficacy of Lodradi Ashchyotana in Vataja Abhishyanda with Special Reference to Simple Allergic Conjunctivitis - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/05/110286

Enrollment

Registered

2026-05-10

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H101- Acute atopic conjunctivitis

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Participants fulfilling all of the following criteria will be included: Age between 18 to 50 years. Patients diagnosed with Simple Allergic Conjunctivitis. Patients presenting with classical signs and symptoms of Vataja Abhishyanda such as itching, redness, watering, pain, and irritation. Patients willing to participate and provide written informed consent. Patients available for follow-up during the study period.

Exclusion criteria

Exclusion criteria: Participants meeting any of the following will be excluded: Patients suffering from other ocular diseases (infective conjunctivitis, glaucoma, uveitis, etc.). History of ocular trauma or eye surgery. Patients with nasolacrimal duct obstruction or dacryocystitis. Severe systemic illness affecting study participation. Known hypersensitivity to study medications. Pregnant or lactating women. Patients unwilling to continue or comply with study protocol.

Design outcomes

Primary

Measure	Time frame
Change in severity score of clinical symptoms of Simple Allergic Conjunctivitis (itching, redness, watering, and pain) assessed using standardized grading scale following administration of Lodradi Ashchyotana compared with control group.Timepoint: 21 Days	—

Secondary

Measure	Time frame
Reduction in oedema (Shopha) Safety and tolerability Recurrence during follow-upTimepoint: Day 7, Day 14, Day 21	—

Countries

India

Contacts

Public ContactDr PRATIKSHA PRADEEP KALE

Kedari Redekar Ayurvedic Mahavidyalaya, PG Training and Research

ayurraga@gmail.com9972616774

Outcome results